Newsletter insight

UK Biotechnology and Technology Transactions Attract Acquisition Interest

Perspectives from the HPC business newsletter.

← All business news UK Biotechnology and Technology Transactions Attract Acquisition Interest
On 19 October, Germany's Merck agreed to acquire UK-based Silence Therapeutics in an approximately $1.3 billion all-cash transaction, strengthening its presence in RNA-targeting medicines. Separately, Intuit's acquisition of UK financial technology startup...
On 19 October, Germany's Merck agreed to acquire UK-based Silence Therapeutics in an approximately $1.3 billion all-cash transaction, strengthening its presence in RNA-targeting medicines. Separately, Intuit's acquisition of UK financial technology startup Sequence highlighted continued interest in British software businesses with specialised AI-enabled commercial applications. Companies pursuing acquisitions, fundraising or strategic partnerships require valuation models, financial due diligence and transaction-risk assessments. HPC supports corporate finance teams with financial modelling, asset valuation and transaction analysis for complex deals at a project cost of $920,000.
Valid number

Read our Privacy Policy to understand how UK Business Investments handles your enquiry and contact details.

Solve the addition to enable the send button.

Let’s start a conversation

Let’s find the right next step for you.

Share your questions and goals. Our team will help you explore the support and opportunities available.

Contact our team